IN2014MN01488A - - Google Patents
Info
- Publication number
- IN2014MN01488A IN2014MN01488A IN1488MUN2014A IN2014MN01488A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A IN 1488MUN2014 A IN1488MUN2014 A IN 1488MUN2014A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A
- Authority
- IN
- India
- Prior art keywords
- mixture
- subunits
- subunit
- mol
- relative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580016P | 2011-12-23 | 2011-12-23 | |
US201261639654P | 2012-04-27 | 2012-04-27 | |
PCT/US2012/071477 WO2013096901A1 (en) | 2011-12-23 | 2012-12-21 | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01488A true IN2014MN01488A (lt) | 2015-04-17 |
Family
ID=48669583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1488MUN2014 IN2014MN01488A (lt) | 2011-12-23 | 2012-12-21 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130189218A1 (lt) |
EP (1) | EP2794582A1 (lt) |
JP (1) | JP2015503635A (lt) |
KR (1) | KR20140121827A (lt) |
CN (1) | CN104024236A (lt) |
IN (1) | IN2014MN01488A (lt) |
TW (1) | TW201332574A (lt) |
UY (1) | UY34542A (lt) |
WO (1) | WO2013096901A1 (lt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2697674T3 (es) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
ES2832711T3 (es) | 2014-10-31 | 2021-06-11 | Abbvie Biotherapeutics Inc | Anticuerpos anti-CS1 y conjugados anticuerpo fármaco |
MX2017007629A (es) | 2014-12-09 | 2018-05-17 | Abbvie Inc | Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen. |
EP3229844B1 (en) | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
EP3383910A1 (en) | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
WO2017095805A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
AU2017239038A1 (en) | 2016-03-22 | 2018-10-04 | Bionomics Inc | Administration of an anti-LGR5 monoclonal antibody |
EP3626273B1 (en) | 2016-05-17 | 2020-12-30 | AbbVie Biotherapeutics Inc. | Anti-cmet antibody drug conjugates and methods for their use |
EP3464400B1 (en) * | 2016-06-03 | 2022-04-06 | Novacyte Therapeutics Company.,LTD | Polymer linkers and their uses |
CN109562169A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
CN116059201A (zh) | 2016-06-08 | 2023-05-05 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
EP3468615A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
MX2018015280A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Conjugados de anticuerpo y farmaco anti-egfr. |
CN116284404A (zh) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
JP2019524649A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗cd98抗体及び抗体薬物コンジュゲート |
BR112018075653A2 (pt) | 2016-06-08 | 2019-08-27 | Abbvie Inc | anticorpos anti-b7-h3 e conjugados anticorpo fármaco |
JP2019521973A (ja) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗bh7−h3抗体及び抗体薬物コンジュゲート |
BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
JP2021530462A (ja) * | 2018-07-03 | 2021-11-11 | フェネック ファーマシューティカルズ,インコーポレイテッド | 無水チオ硫酸ナトリウムの製剤化 |
EP3927729A4 (en) | 2019-02-18 | 2023-10-11 | Eli Lilly and Company | THERAPEUTIC ANTIBODY FORMULATION |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
SG11202111281TA (en) | 2019-05-21 | 2021-12-30 | Novartis Ag | Cd19 binding molecules and uses thereof |
AU2020327000A1 (en) | 2019-08-08 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
BR112022008552A2 (pt) | 2019-11-05 | 2022-08-09 | Regeneron Pharma | Moléculas de ligação multiespecíficas de scfv de terminal-n |
WO2021142086A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
JP2023516080A (ja) | 2020-03-06 | 2023-04-17 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
CN116249549A (zh) | 2020-03-27 | 2023-06-09 | 诺华股份有限公司 | 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
CA2706914A1 (en) * | 2007-11-28 | 2009-06-11 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
EP2435053B1 (en) * | 2009-05-28 | 2018-11-14 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
-
2012
- 2012-12-21 US US13/725,900 patent/US20130189218A1/en not_active Abandoned
- 2012-12-21 UY UY0001034542A patent/UY34542A/es not_active Application Discontinuation
- 2012-12-21 JP JP2014548983A patent/JP2015503635A/ja active Pending
- 2012-12-21 WO PCT/US2012/071477 patent/WO2013096901A1/en active Application Filing
- 2012-12-21 KR KR1020147020754A patent/KR20140121827A/ko not_active Application Discontinuation
- 2012-12-21 IN IN1488MUN2014 patent/IN2014MN01488A/en unknown
- 2012-12-21 EP EP12858970.2A patent/EP2794582A1/en not_active Withdrawn
- 2012-12-21 TW TW101149115A patent/TW201332574A/zh unknown
- 2012-12-21 CN CN201280063450.4A patent/CN104024236A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20140121827A (ko) | 2014-10-16 |
WO2013096901A1 (en) | 2013-06-27 |
EP2794582A1 (en) | 2014-10-29 |
US20130189218A1 (en) | 2013-07-25 |
CN104024236A (zh) | 2014-09-03 |
TW201332574A (zh) | 2013-08-16 |
WO2013096901A8 (en) | 2014-08-07 |
JP2015503635A (ja) | 2015-02-02 |
UY34542A (es) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01488A (lt) | ||
EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
MX2018008061A (es) | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. | |
CY1120557T1 (el) | Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων | |
MX347644B (es) | Macromoleculas estrella para el cuidado personal y del hogar. | |
MX2010009154A (es) | Moleculas conjugadas del factor viii. | |
WO2012135025A3 (en) | Conjugated lipomers and uses thereof | |
IN2014DN00101A (lt) | ||
GB201008902D0 (en) | Membrane enhanced polymer sythesis | |
EA201200617A1 (ru) | Полимеры на основе циклодекстрина для доставки лекарственных средств | |
MX352245B (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica. | |
EP2555741A4 (en) | SPRAYABLE COMPOSITION COMPRISING A POLYMER FILLED WITH HIGH MOLECULAR WEIGHT | |
MX2012000575A (es) | Conjugados de epsilon-polilisina y uso de los mismos. | |
BR112013028365A2 (pt) | "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer". | |
UA101497C2 (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
ZA200707973B (en) | Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids | |
MX2014004927A (es) | Composiciones para el cuidado del cabello. | |
IN2014CN03735A (lt) | ||
BR112014004644A2 (pt) | polímeros funcionalizados com lactonas ou tiolactonas contendo um grupo amino protegido | |
EA201270186A1 (ru) | Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений | |
WO2013186632A3 (en) | Conjugates of biologically active molecules to functionalized polymers | |
WO2013013753A3 (en) | Polymers and oligomers with functionalized side groups | |
MX2012006265A (es) | Formulaciones disacaridas hipersulfatadas. | |
WO2011130716A3 (en) | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers | |
BR112014016177A2 (pt) | composição de cloreto de polivinila, tubo, calha ou tanque, uso de uma composição de pvc e uso de tubo, calha ou tanque |